Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced today that the CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) combination therapy for advanced solid tumors (IND) has been approved by the China National Drug Administration (NMPA).

Zhitongcaijing · 11/04/2025 00:09
Zhitong Finance App News, Cornerstone Pharmaceutical-B (02616.HK) announced today that the CS2009 (PD-1/VEGF/CTLA-4 tri-specific antibody) combination therapy for advanced solid tumors (IND) has been approved by the China National Drug Administration (NMPA).